直接口服抗凝药在低体重非瓣膜性房颤患者中的应用
本研究基于韩国国民健康保险数据库,比较低体重(≤60 kg)非瓣膜性房颤患者使用直接口服抗凝药(DOAC)与华法林的疗效与安全性。结果显示,DOAC 较华法林降低缺血性卒中、大出血及颅内出血风险,净临床获益更优,且在体重<50 kg 患者中结果一致。
要点
- 低体重房颤患者中,DOAC 较华法林降低缺血性卒中和大出血风险。
- DOAC 的获益主要来自颅内出血减少,净临床获益更优。
- 体重<50 kg 患者中 DOAC 的净临床获益与总体人群一致。
核心结论
- 在低体重亚洲房颤人群中,DOAC 的有效性和安全性优于华法林。
- 极低体重患者中结果一致,常规剂量与减量 DOAC 的有效性和安全性相当。
研究设计与样本
- 纳入体重≤60 kg 并接受口服抗凝药的房颤患者,DOAC 组 14,013 例,华法林组 7,576 例,采用倾向评分加权平衡两组。
主要发现
- DOAC 组缺血性卒中风险低于华法林(HR 0.591;95%CI 0.510-0.686)。
- DOAC 组大出血风险低于华法林(HR 0.705;95%CI 0.601-0.825),主要因颅内出血减少(HR 0.554;95%CI 0.429-0.713)。
- DOAC 组复合结局风险低于华法林(HR 0.660;95%CI 0.606-0.717),体重<50 kg 患者中复合结局 HR 0.665(95%CI 0.581-0.762)。
临床怎么用
- 低体重非瓣膜性房颤患者优先考虑 DOAC 而非华法林以降低卒中和出血风险。
- 极低体重患者使用 DOAC 的获益与总体低体重人群一致。
- 常规剂量与减量 DOAC 在低体重患者中的有效性和安全性相当。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is unclear whether the overall effectiveness and safety of direct oral anticoagulants (DOACs) are consistent in patients with nonvalvular atrial fibrillation (AF) and extremely low body weight (<50 kg). OBJECTIVES: This study compared DOACs with warfarin in AF patients with low body weight. METHODS: Using data from the Korean National Health Insurance Service database from January 2014 to December 2016, AF patients with body weight ≤60 kg and who were treated with oral anticoagulants (n = 14,013 taking DOACs and n = 7,576 taking warfarin) were included and examined for ischemic stroke, intracranial hemorrhage (ICH), gastrointestinal bleeding, major bleeding, all-cause death, and composite outcome. The propensity score weighting was used to balance the 2 groups. RESULTS: Baseline characteristics were well balanced between the 2 groups (mean age 73 years, mean CHA2DS2-VASc score 4, and 28% of patients weighed <50 kg). DOACs were associated with lower risks of ischemic stroke (hazard ratio [HR]: 0.591; 95% confidence interval [CI]: 0.510 to 0.686) and major bleeding (HR: 0.705; 95%: CI 0.601 to 0.825), which were caused by a reduction in ICH (HR: 0.554; 95% CI: 0.429 to 0.713) compared with warfarin. DOAC improved the net clinical benefit compared with warfarin (HR for composite outcome: 0.660; 95% CI: 0.606 to 0.717), and this was consistent in patients who weighed <50 kg (HR for composite outcome: 0.665; 95% CI: 0.581 to 0.762). CONCLUSIONS: In this real-world Asian AF population with low body weight, DOACs showed better effectiveness and safety than warfarin. These results were consistent in patients with extremely low body weight. Regular dosages of DOACs showed comparable results as reduced dosages of DOACs in both effectiveness and safety.
引用
- Lee SR, Choi EK, Park CS, et al. Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Low Body Weight. J Am Coll Cardiol. 2019. PMID: 30819360. doi:10.1016/j.jacc.2018.11.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。